INTRODUCTION {#s0}
============

Malaria is a mosquito-borne infection caused by protozoan parasites of the *Plasmodium* genus. Of the six *Plasmodium* species known to infect humans ([@B1][@B2][@B3]), *P. vivax* is the most widely distributed, causing approximately half of all clinical cases of malaria outside Africa ([@B4]). Whole-genome sequencing (WGS) of *Plasmodium* parasites from clinical samples has revealed important insights into the biology, epidemiology, and mechanisms of drug resistance of malaria ([@B5][@B6][@B12]). For *P. vivax*, WGS of clinical isolates has the potential to uncover mechanisms underlying some of the unique aspects of this parasite's biology, such as distinguishing between reinfection and relapse due to activation of dormant liver parasites. However, WGS of *P. vivax* from clinical samples is challenging, mainly due to low parasite densities in clinical samples compared to those of *Plasmodium falciparum* and the lack of a robust *ex vivo* culture system.

Multiple techniques have been developed to enrich *Plasmodium* genomic DNA (gDNA) from clinical samples, including leukocyte depletion ([@B13][@B14][@B15]), hybrid selection with RNA baits ([@B16], [@B17]), short-term *ex vivo* culture ([@B18]), adaptation to growth in splenectomized monkeys ([@B9], [@B19]), and single-cell sequencing ([@B20]). The majority of these techniques require significant labor and resources. While leukocyte depletion is the most cost-effective, it requires sample processing within 6 h of sample collection, which is not feasible at many field sites and is not always effective. Two recent studies that performed WGS on over 400 clinical isolates of *P. vivax* ([@B15], [@B17]) employed hybrid selection and leukocyte depletion to enrich *P. vivax* gDNA from clinical samples. Pearson et al. used leukocyte depletion on 292 clinical samples and had to eliminate 144 (49%) of their samples from further population genetics analysis due to low quality, which often occurs due to contaminating human DNA ([@B15]). Hupalo et al. used hybrid selection to enrich their samples, with 31 out of 170 sequences (21%) removed from further analysis due to low quality ([@B17]). Although more frequently successful, the hybrid selection technique requires either expensive synthetic RNA baits or a large amount of pure *P. vivax* DNA to create the RNA baits, which is difficult to obtain. In addition, hybrid selection can introduce bias, since it is approximately half as efficient at capturing regions with GC contents of \>50% ([@B16]).

An alternative method is selective whole-genome amplification (SWGA). SWGA has been used to enrich submicroscopic DNA levels of the ape *Plasmodium* parasites, *P. reichenowi* and *P. gaboni*, from whole-blood samples ([@B21], [@B22]) and *P. falciparum* genomes from dried blood spots ([@B23]) for WGS. SWGA preferentially amplifies the genomes of pathogens from complex mixtures of target and host DNA ([Fig. 1](#fig1){ref-type="fig"}) ([@B24]). SWGA does not require separation of target DNA from background DNA, making it an attractive option for pathogens that cannot be amplified in culture. DNA amplification is carried out by the highly processive, strand-displacing phi29 DNA polymerase and a set of pathogen-specific primers that target short (6 to 12 nucleotide) motifs that are common in the pathogen genome and uncommon in the host genome. The strand displacement function of phi29 results in the amplification of genomic regions where primers bind frequently, leading to the preferential amplification of genomes with frequent primer-binding sites. Here, we show that SWGA efficiently enriches *P. vivax* gDNA from unprocessed human blood samples and dried blood spots for cost-effective, high-quality whole-genome sequencing.

![Selective whole-genome amplification (SWGA) of *Plasmodium vivax* genomic DNA (gDNA) from human blood samples. (A) SWGA primers bind frequently to *Plasmodium vivax* gDNA and infrequently to human gDNA. (B) When phi29 encounters double-stranded gDNA, it displaces the newly synthesized strand, opening new primer binding sites on the synthesized gDNA, leading to selective amplification of templates with frequent primer binding sites. (C) Post-SWGA, the percentage of *P. vivax* DNA has increased relative to the percentage of host DNA.](mbo0011731660001){#fig1}

RESULTS {#s1}
=======

Primer design and optimization using *P. vivax*-infected whole-blood samples. {#s1.1}
-----------------------------------------------------------------------------

To perform SWGA on *P. vivax* gDNA from unprocessed human blood samples, we designed primers that specifically amplified this parasite's DNA using a previously published approach for *P. falciparum* ([@B22]). Briefly, we identified the most frequently occurring motifs of 6 to 12 nucleotides in length in the *P. vivax* Salvador-1 (Sal-1) reference genome. We selected the top 10,000 primers of each length, yielding a total of 70,000 primers for further analysis. We filtered these primers based on characteristics such as melting temperature (18 to 32°C), ability to homodimerize (no greater than 3 consecutive matches), binding frequencies on the human genome and Sal-1 genome (less frequent than once every 500,000 bp and more frequent than once every 50,000 bp, respectively), and infrequent binding of the human mitochondrial genome (less than 4 binding sites). Next, we removed primers predicted to bind the Sal-1 subtelomeres. These filters resulted in a pool of 222 primers. We separated these primers into 6 sets that were predicted not to form heterodimers and identified the top set (pvset1) of 10 primers using a selection algorithm described previously ([@B22]). gDNA from an unprocessed *P. vivax*-infected whole-blood sample (MRL2) was subjected to SWGA with primer set pvset1 prior to shotgun sequencing (see [Fig. S1](#figS1){ref-type="supplementary-material"} in the supplemental material). SWGA significantly increased the percentage of reads that mapped to the *P. vivax* Sal-1 reference genome, from 0.7% to 73.5% (see [Fig. S1A](#figS1){ref-type="supplementary-material"}), and improved the genome coverage obtained from \~80 million bp of sequencing from 1.5% to 58% (see [Fig. S1B](#figS1){ref-type="supplementary-material"}).
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Testing of SWGA primer sets on an unprocessed, *P. vivax*-infected blood sample. (A) Unamplified DNA (black) and DNA amplified with SWGA primer set pvset1 (blue) was sequenced on a MiSeq (Illumina). The percentage of MiSeq reads that mapped to the *P. vivax* Sal-1 reference genome in Geneious (version 9.1) was plotted for both the unamplified and SWGA-amplified sample. (B) Rarefaction analysis compares the ≥1× *P. vivax* genome coverage relative to total sequencing depth (in millions of base pairs sequenced) with and without SWGA. Download FIG S1, TIF file, 69.2 MB.
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We observed that the genome coverage obtained per base pair sequenced was lower than that achieved with SWGA of *P. falciparum* gDNA using the same primer set design methods ([@B22]). Visual inspection of the *P. vivax* genome coverage from samples subjected to SWGA revealed that coverage gaps were typically in regions with comparatively higher GC content ([Fig. 2A](#fig2){ref-type="fig"}). The *P. falciparum* genome is extremely AT rich, with only 19.4% of bases consisting of G's or C's, while the GC content for the *P. vivax* genome is 42.3% ([@B9]). The *P. vivax* genome also has an isochore structure: internal chromosomal areas have a high GC content and subtelomeres and centromeres have lower GC contents ([@B25]). Since phi29 DNA polymerase pauses more frequently during strand displacement and primer extension in regions with a high GC content of DNA ([@B26]), we hypothesized that differences in base composition could explain the more uneven amplification of the *P. vivax* genome compared to that of *P. falciparum*.

![*Plasmodium vivax* chromosomal coverage following SWGA using primer set pvset1 (A) or pvset1920 (B). The base compositions of chromosomes 2 and 6 were visualized in Geneious (version 9.1) using the *P. vivax* Sal-1 reference genome; green and blue lines represent percentages of AT and GC content, respectively, plotted for 25-bp windows across the chromosome (scale shown above the graph). Shown in blue and red below are the corresponding MiSeq read coverage depths using primer sets pvset1 and pvset1920, respectively. Coverage plots were generated using IGVTools (version 2.3.40) and are shown on a log scale with maximum read depth indicated in the upper left corner of the plot.](mbo0011731660002){#fig2}

We thus designed primer sets specifically targeting regions of the *P. vivax* Sal-1 reference genome with high GC content and poor coverage using the *swga* program (<https://github.com/eclarke/swga>; unpublished data), a program that identifies and scores SWGA primer sets (see [Fig. S2](#figS2){ref-type="supplementary-material"} in the supplemental material). Primers were designed to bind regions of the *P. vivax* Sal-1 genome that had even AT/GC composition, were longer than 195,000 bp, and had low sequence coverage when amplified with pvset1. We identified 1,939 primer sets (consisting of up to 15 primers) with minimal human genome binding and maximal *P. vivax* genome binding and scored them based on evenness of binding, as well as mean distance between primer binding sites in the foreground and background genomes. The primer set with the best score, pvset1920, was chosen for subsequent testing. SWGA of an unprocessed human blood sample with pvset1920 yielded overall superior *P. vivax* genome coverage compared to that of SWGA with pvset1 ([Fig. 3](#fig3){ref-type="fig"}). Visual inspection of these post-SWGA *P. vivax* sequences revealed that pvset1920 achieved improved coverage particularly in regions with high GC content ([Fig. 2B](#fig2){ref-type="fig"}), with troughs in coverage in genomic regions of lower GC content, which include the centromeres and subtelomeres.
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Flowchart describing the process of SWGA primer set selection for *Plasmodium vivax*. \*, selected regions are \>195,000 bp in length with an average 48.5 to 50.6% GC composition. The *swga* program is available on (<https://github.com/eclarke/swga>; unpublished data). Download FIG S2, TIF file, 31.4 MB.
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![Testing of SWGA primer sets on DNA from an unprocessed, *P. vivax*-infected blood sample. (A) Unamplified DNA (black) and DNA amplified with SWGA primer set pvset1 (blue) or pvset1920 (red) was sequenced on a MiSeq (Illumina). The percentages of MiSeq reads that mapped to the *P. vivax* Sal-1 reference genome in Geneious (version 9.1) ([@B39]) were plotted for both unamplified and SWGA-amplified samples. (B) The 1× *P. vivax* genome coverage is shown relative to the total sequencing depth (in millions of base pairs sequenced) for samples subjected to SWGA with pvset1920 or pvset1 and for unamplified DNA.](mbo0011731660003){#fig3}

Having developed a method that worked well for SWGA of *P. vivax* gDNA from whole blood, we tested whether the method could also be applied to gDNA extracted from dried blood spot samples. Dried blood spots are a common method of storing patient and parasite DNA that utilizes a smaller volume of blood and does not require immediate cold storage. DNA extracted from dried blood spots can have variable quality depending on the method of collection and storage ([@B27]). SWGA has been used to enrich *P. falciparum* DNA from dried blood spots for WGS ([@B23]), with an average of 48.1% ± 3.5% of the genome covered at ≥5× for samples with an average parasite density of 73,601 parasites/µl ± 19,399 (1.5% parasitemia). Since *P. vivax* clinical samples generally have lower parasite densities, we wondered if it would be feasible to obtain significant genome coverage on *P. vivax* from dried blood spots with SWGA. We extracted DNA from blood spots obtained from symptomatic patients in Peru and performed SWGA with pvset1920, achieving 73% and 42% genome coverage at 1× on initial testing for samples with a high (sample C, 56,790 parasites/µl; 1.1%) and low (sample L, 2,572 parasites/µl; 0.05%) level of parasitemia, respectively (see [Fig. S3](#figS3){ref-type="supplementary-material"} in the supplemental material).
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Testing of SWGA primer set pvset1920 on DNA from *P. vivax* patient-derived dried blood spots. Genomic DNA from two dried blood spots with either a relatively high (sample C, 56,790 parasites/µl) or low (sample L, 2,572 parasites/µl) parasite density was subjected to SWGA with pvset1920 and sequenced on a MiSeq (Illumina). The percentages of the *P. vivax* genome with ≥1× coverage are shown relative to total sequencing depth (in millions of base pairs sequenced). Download FIG S3, TIF file, 10.6 MB.
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We finally tested whether an enzymatic digest to remove contaminating human DNA could further improve *P. vivax* genome coverage. Modification-dependent restriction endonucleases (MDREs), such as MspJI and FspEI, which specifically recognize cytosine C-5 methylation or hydroxymethylation ([@B28]), have been used to selectively degrade human DNA in *P. falciparum* clinical samples. Enzyme digest of DNA extracted from clinical samples with \>80% human contamination has previously been shown to enrich *P. falciparum* DNA \~ninefold for more efficient WGS ([@B29]). However, when we performed a digest with MspJI and FspEI enzymes on gDNA extracted from whole blood obtained from patients with *P. vivax* infection, we observed either no change or markedly decreased genome coverage in the 5 enzyme-digested samples (see [Fig. S4](#figS4){ref-type="supplementary-material"} in the supplemental material).
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Comparison of SWGA following either a mock digestion or methylation-dependent restriction digest. Genomic DNA extracted from five *P. vivax*-infected patient samples was subjected to a mock digest or digest with the methylation-dependent restriction enzymes MspJI and FspEI. The percentage of the *P. vivax* reference genome covered (1×) by mapping 200,100 MiSeq (Illumina) reads (approximately 25 million bp of sequencing depth) from each sample with or without digest is shown. Statistical significance was calculated using a two-tailed *t* test. Download FIG S4, TIF file, 31.4 MB.
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SWGA and WGS of *P. vivax* from patient samples. {#s1.2}
------------------------------------------------

To test the utility of SWGA for variant calling and population genetics analysis of *P. vivax* from unprocessed clinical blood samples, we used primer set pvset1920 to perform SWGA on *P. vivax* gDNA from 18 whole-blood and 4 dried blood spot samples collected from symptomatic patients with *P. vivax* infection in Peru. Since the whole-blood samples had not been leukocyte filtered, they had significant contamination with human DNA, with less than 1.5% of reads mapping to the Sal-1 reference genome in unamplified samples (not shown). For all samples, SWGA significantly increased the proportion of reads that mapped to the *P. vivax* Sal-1 reference genome, resulting in higher genome coverage and higher percentages of callable total- and core-genome regions (covered by ≥5 reads) ([Table 1](#tab1){ref-type="table"}). Comparison of the SWGA-amplified samples to 10 leukocyte-filtered samples from a field study in Peru which were sequenced to a similar depth (1.5 ± 0.2 billion bp sequenced for SWGA samples versus 1.5 ± 0.5 billion bp for leukocyte-filtered samples) showed that SWGA yields a twofold increase in the percentage of sequencing reads that map to the*P. vivax* genome and an average 5× *P. vivax* core-genome coverage of 60.1% ± 26.0%, compared to 43.7% ± 41.4% for leukocyte-filtered samples ([@B10]). For the 4 dried blood spot samples, we achieved an average 5× core-genome coverage of 54.0% ± 34.6%.

###### 

Sequencing statistics for *P. vivax* sequences from clinical samples that underwent selective whole-genome amplification[^a^](#ngtab1.1){ref-type="table-fn"}

  Enrichment technique(sample)                   No. of parasites/µl(% parasitemia)[^b^](#ngtab1.2){ref-type="table-fn"}   Total no. of bp sequenced (billions)   Reads aligned to *P. vivax*reference (%)   Mean coverage (×)   \% callable[^c^](#ngtab1.3){ref-type="table-fn"}:   
  ---------------------------------------------- ------------------------------------------------------------------------- -------------------------------------- ------------------------------------------ ------------------- --------------------------------------------------- -------------
  SWGA (18 whole-blood samples)                                                                                                                                                                                                                                                      
      1                                          45,680 (0.9)                                                              1.42                                   89.5                                       37.1                71.7                                                83.6
      2                                          34,268 (0.7)                                                              1.68                                   80.9                                       37.9                72.9                                                85.1
      3                                          28,474 (0.6)                                                              1.41                                   88.3                                       30.4                66.6                                                76.3
      4                                          25,680 (0.5)                                                              1.50                                   65.1                                       13.8                40.2                                                42.1
      5                                          19,241 (0.4)                                                              2.00                                   71.9                                       44.1                79.9                                                95.4
      6                                          13,064 (0.3)                                                              1.84                                   83.7                                       43.8                76.1                                                90.4
      7                                          11,438 (0.2)                                                              1.52                                   79.5                                       20.3                32.7                                                34.5
      8                                          9,961 (0.2)                                                               1.36                                   75.4                                       31.0                74.6                                                87.3
      9                                          8,842 (0.2)                                                               1.84                                   74.2                                       29.6                72.9                                                84.7
      10                                         7,382 (0.1)                                                               1.23                                   72.6                                       23.7                65.6                                                73.6
      11                                         6,258 (0.1)                                                               1.41                                   82.8                                       25.1                59.5                                                67.7
      12                                         5,135 (0.1)                                                               1.82                                   54.9                                       18.0                34.8                                                37.0
      13                                         2,942 (0.06)                                                              1.16                                   40.7                                       12.9                52.1                                                57.9
      14                                         1,873 (0.04)                                                              1.44                                   17.0                                       5.7                 13.7                                                14.1
      15                                         1,652 (0.03)                                                              1.52                                   53.2                                       23.5                52.0                                                57.3
      16                                         1,471 (0.03)                                                              1.26                                   44.0                                       12.9                21.5                                                22.9
      17                                         537 (0.01)                                                                1.92                                   22.5                                       11.1                38.1                                                40.7
      18                                         495 (0.01)                                                                1.44                                   28.6                                       10.0                30.0                                                30.5
      Avg ± SD                                   12,466 ± 13,107.2                                                         1.5 ± 0.2                              62.7 ± 23.2                                23.9 ± 11.8         53.1 ± 20.9                                         60.1 ± 26.0
  SWGA (4 dried bloodspot samples)                                                                                                                                                                                                                                                   
      DBS-4                                      50,330 (1.0)                                                              1.97                                   79.4                                       34.8                74.4                                                87.4
      DBS-3                                      35,730 (0.7)                                                              1.91                                   46.8                                       20.9                69.5                                                80.3
      DBS-2                                      5,932 (0.1)                                                               0.93                                   11.0                                       3.0                 25.8                                                24.2
      DBS-1                                      3,885 (0.08)                                                              1.57                                   17.7                                       4.2                 23.2                                                24.1
      Avg ± SD                                   23,962 ± 22,826.4                                                         1.6 ± 0.5                              38.7 ± 27.1                                15.7 ± 13.1         48.2 ± 27.5                                         54.0 ± 34.6
  Leukocyte filtration(10 whole-blood samples)                                                                                                                                                                                                                                       
      Mdio01                                     NA                                                                        2.43                                   25.7                                       6.35                8.2                                                 5.5
      Mdio02                                     NA                                                                        0.80                                   16.2                                       1.65                1.3                                                 0.6
      Mdio03                                     NA                                                                        2.04                                   19.9                                       8.23                57.2                                                61.2
      Mdio04                                     NA                                                                        1.52                                   14.2                                       1.97                18.7                                                9.6
      Mdio05                                     NA                                                                        1.56                                   49                                         22.3                78.1                                                91.7
      Mdio06                                     NA                                                                        1.62                                   55.4                                       28.1                79.6                                                93.4
      Mdio07                                     NA                                                                        1.46                                   20.7                                       4.23                15.8                                                11.3
      Mdio08                                     NA                                                                        1.50                                   30.3                                       10.6                67.3                                                74.9
      Mdio09                                     NA                                                                        0.74                                   18.3                                       1.74                1.6                                                 0.8
      Mdio10                                     NA                                                                        1.26                                   43.5                                       16.1                76                                                  88.1
      Avg ± SD                                   NA                                                                        1.5 ± 0.5                              31.4 ± 14.8                                10.1 ± 9.2          40.4 ± 34.0                                         43.7 ± 41.4

Sequencing statistics were determined using the Genome Analysis Toolkit's (GATK) DepthofCoverage tool. The core genome was defined by coordinates determined in the large-scale *P. vivax* sequencing study by Pearson et al. ([@B15]). The leukocyte-filtered sequencing statistics presented here are from *P. vivax* clinical samples obtained from a previously published study in Peru ([@B10]).

NA, not applicable.

Covered by ≥5 reads.

There was a trend toward improved mean coverage and percentage of the genome callable in samples with higher parasite densities (see [Fig. S5](#figS5){ref-type="supplementary-material"} in the supplemental material). This is consistent with previous SWGA results for *P. falciparum* ([@B22]) and results from other *P. vivax*-enriching methods, such as hybrid selection ([@B16]). Samples subjected to SWGA yielded similar ≥5× genome coverage per sequenced base pair compared to that obtained by direct sequencing of a leukocyte-filtered patient sample ([Fig. 4A](#fig4){ref-type="fig"}). The percentage of the 14 large chromosomes of *P. vivax* considered callable for samples that underwent SWGA fell within the range of that obtained by direct sequencing of leukocyte-filtered samples ([Fig. 4B](#fig4){ref-type="fig"}). Additionally, post-SWGA sequences yielded similar levels of mean base quality when normalized across 100-bp windows of various %GC contents in the reference genome compared to the results for leukocyte-filtered samples ([Fig. 5](#fig5){ref-type="fig"}).
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Sequencing statistics for *Plasmodium vivax* clinical samples with various parasite densities. The percentage of reads that map to *P. vivax* Sal-1 (blue circles), the mean *P. vivax* genome coverage (green squares), and the percentage of the *P. vivax* genome covered by ≥5 reads (red triangles) are shown for all 18 samples amplified by SWGA, with sample parasitemia indicated on the *x* axis. Sequencing statistics were determined using the Genome Analysis Toolkit (GATK) DepthOfCoverage tool. Download FIG S5, TIF file, 31.4 MB.
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![Comparison of *P. vivax* genome coverage generated from samples treated with SWGA and with leukocyte filtration. (A) *P. vivax* genome coverage (5×) is shown relative to total sequencing depth (in millions of base pairs sequenced) for a sample amplified with pvset1920 (sample 5) and for a leukocyte-filtered sample (Mdio6). Both samples were sequenced on an Illumina HiSeq. (B) The percentages of the 14 chromosomes that were callable (covered by ≥5 reads) for samples that underwent SWGA (colored lines) or leukocyte filtration (black dashed lines) were compared between multiple samples.](mbo0011731660004){#fig4}

![GC bias plots for *P. vivax* genomes generated following leukocyte filtration (A) or SWGA (B). GC bias plots were generated using Picard (version 2.0.1) on aligned sequencing reads from two different clinical samples that underwent leukocyte filtration (A) or selective whole-genome amplification (B). The number of windows with a given GC content are plotted with red bars; the base quality (green line) and normalized coverage (open blue circles) are plotted for different levels of GC content for both methods of *P. vivax* gDNA enrichment.](mbo0011731660005){#fig5}

Variant analysis. {#s1.3}
-----------------

To examine the utility of post-SWGA sequences for variant analysis, we called 45,821 single-nucleotide polymorphisms (SNPs) from the whole-blood and dried blood spot samples that were subjected to SWGA. For the whole-blood samples, an average of 14,463 SNPs was identified per sample, which is consistent with prior studies of *P. vivax* field isolates ([@B10]). Compared to the results for leukocyte-filtered samples, SNP characteristics such as SNP rate, transition-to-transversion (Ti/Tv) ratio, and nonsynonymous-to-synonymous ratio were nearly identical in the samples that underwent SWGA ([Table 2](#tab2){ref-type="table"}).

###### 

Comparison of single-nucleotide polymorphism characteristics of *Plasmodium vivax* sequences after selective whole-genome amplification (SWGA) and leukocyte filtration[^a^](#ngtab2.1){ref-type="table-fn"}

  Sample preparation method   SNP characteristic   Nonsynonymous-to-synonymous ratio (SNP effect)                                     
  --------------------------- -------------------- ------------------------------------------------ ----------- ------------- ------- ------
  SWGA                        1.41                 20,865 (40)                                      3,714 (7)   25,178 (49)   0.002   1.63
  Leukocyte filtration        1.36                 18,365 (40)                                      3,029 (7)   23,157 (50)   0.002   1.74

Samples for SWGA were obtained from Iquitos, Peru, and samples for leukocyte filtration were from a previously published study done in Madre de Dios, Peru ([@B10]).

In addition, the proportions of SNPs that were exonic, intronic, intergenic, or at 5′ and 3′ untranslated regions were similar between samples prepared using the two methods of *P. vivax* enrichment. We also detected SNPs in several known drug resistance genes previously detected in samples from Peru ([@B10]) and Colombia ([@B8]) in the whole-blood and dried blood spot samples ([Table 3](#tab3){ref-type="table"}; see also [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material), further validating the utility of sequences derived from SWGA for variant calling. This includes several intronic mutations around a putative chloroquine resistance transporter gene (*pvcrt*), in addition to coding mutations in the dihydrofolate reductase (*pvdhfr*), multidrug resistance protein 1 (*pvmdr1*), multidrug resistance protein 2 (*pvmrp2*), and dihydropteroate synthetase (*dhps*) genes.
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Drug resistance mutations in *Plasmodium vivax* sequences from dried blood spot DNA subjected to SWGA. Download TABLE S1, DOCX file, 0.01 MB.
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###### 

Nonsynonymous SNPs in known drug resistance genes detected in *Plasmodium vivax* samples that underwent selective whole-genome amplification (SWGA)

  Locus                    Chromosome   Position   Reference allele[^a^](#ngtab3.1){ref-type="table-fn"}   Alternate allele[^b^](#ngtab3.2){ref-type="table-fn"}   Amino acid change[^c^](#ngtab3.3){ref-type="table-fn"}   No. of samples bearing indicated allele(no. confidently genotyped)
  ------------------------ ------------ ---------- ------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------------------
  *pvcrt-0* (PVX_087980)   1            331151     T                                                       C                                                       Intron                                                   17 (18)
                                        331819     G                                                       A                                                       Intron                                                   11 (18)
                                        332453     T                                                       C                                                       Intron                                                   18 (18)
                                        332874     A                                                       C                                                       Intron                                                   18 (18)
  *pvdhfr* (PVX_089950)    5            964763     C                                                       G, A                                                    Ser58Arg                                                 12 (12)
                                        964939     G                                                       A                                                       Ser117Asn                                                16 (16)
  *pvmdr1* (PVX_080100)    10           363223     A                                                       G                                                       Thr958Met                                                12 (12)
                                        363374     T                                                       G                                                       Met908Leu                                                11 (11)
                                        365435     C                                                       A                                                       Val221Leu                                                1 (12)
  *pvmrp2* (PVX_124085)    14           2043859    G                                                       C                                                       Gln1407Glu                                               11 (13)
                                        2045050    C                                                       T                                                       Val1010Met                                               14 (15)
                                        2047090    G                                                       A                                                       Pro330Ser                                                1 (15)
                                        2047233    C                                                       A                                                       Arg282Met                                                13 (14)
                                        2047816    C                                                       G                                                       Glu88Gln                                                 3 (18)
  *dhps* (PVX_123230)      14           1257856    G                                                       C                                                       Ala383Gly                                                9 (15)
                                        1258389    C                                                       T                                                       Met205Ile                                                10 (12)

Allele of the *P. vivax* Sal-1 reference genome at the indicated position.

Allele found in *P. vivax* samples from Peru that underwent SWGA.

Amino acid change resulting from base change from the reference to the alternate allele.

We also compared sample clonality estimates of post-SWGA sequences to microsatellite analyses on the same unamplified samples. We estimated the clonality of the 6 post-SWGA sequences with the highest coverage using the *F*~*ws*~ statistic, a measure of within-host diversity previously used to characterize multiplicity of infection in *Plasmodium falciparum* patient samples ([Table 4](#tab4){ref-type="table"}) ([@B5], [@B30]). An *F*~*ws*~ score of ≥0.95 indicates low within-host diversity and infection with a single parasite, while an *F*~*ws*~ score of ≤0.70 is suggestive of a multiclonal infection. Microsatellite analysis on these same 6 unamplified samples indicated that all were clonal, except for sample 9, where the presence of 2 microsatellite markers at more than one position suggested that it could be a multiclonal sample. However, for all 6 post-SWGA sequences, the *F*~*ws*~ score was ≥0.95, suggesting that all were clonal infections. Thus, while SWGA does not introduce errors that lead to a falsely low *F*~*ws*~, it may lead to underestimations of clonality in multiclonal samples.

###### 

Clonality estimates of samples that underwent selective whole-genome amplification compared to microsatellite analysis from the unamplified samples

  Sample   *F~ws~*   No. of heterozygous SNPs   No. of microsatellite markers before SWGA in microsatellite locus:                                    
  -------- --------- -------------------------- -------------------------------------------------------------------- ----- ------- -------- --------- -----
  1        0.98      377                        266                                                                  170   102     85       149       153
  2        0.97      446                        266                                                                  170   102     85       149       163
  5        0.97      372                        266                                                                  171   102     86       150       153
  6        0.98      326                        266                                                                  170   102     86       149       153
  8        0.98      300                        282                                                                  167   102     94       136       134
  9        0.97      354                        282                                                                  163   99,94   86,118   143,150   151

Finally, we constructed a neighbor-joining tree using core-genome SNPs to determine the relatedness of our samples to one another and to other *P. vivax* isolates from Peru and around the world ([Fig. 6](#fig6){ref-type="fig"}). In this tree, our samples, which were from the Iquitos region of Peru, clustered with one another and were most closely related to leukocyte-filtered samples from another region of Peru ([@B10]). They also exhibited the expected degree of relatedness to previously published *P. vivax* sequences derived from other leukocyte-filtered ([@B15]), hybrid-selected ([@B17]), and monkey-adapted ([@B19]) clinical samples from diverse areas of the world, further validating the use of post-SWGA sequences from downstream analyses.

![Neighbor-joining tree of *Plasmodium vivax* clinical samples from different regions of the world. The tree was constructed with core-genome-wide SNP data from *P. vivax* samples that underwent selective whole-genome amplification (Peru-SWGA-1 through Peru-SWGA-18) and *P. vivax* clinical samples from previously published studies that underwent leukocyte filtration ([@B15]) (Thailand-PD0169, Thailand-PD0168, Thailand-PD0166, Thailand-PD-0167, PNG-0050, PNG-0065, PNG-0068, Vietnam-PV0025, Vietnam-PV0053, Vietnam-PV0056, and Vietnam-PV0061), hybrid selection ([@B17]) (Colombia-30102100437, Colombia-490, Colombia-438−A, Colombia-30101099036, Thailand-VKTS-36, Thailand-VKBT-73, Thailand-VKBT-58, Thailand VKBT-71, Thailand-VKBT-100, PNG-73, PNG-58, PNG-012, PNG-014, and PNG-025), or adaption to growth in splenectomized monkeys ([@B19]) (BrazilI and IndiaVII) prior to sequencing. Bootstrap values are shown on each corresponding branch.](mbo0011731660006){#fig6}

DISCUSSION {#s2}
==========

In this study, we validate SWGA as a cost-effective, robust method to enrich *P. vivax* gDNA from unprocessed whole-blood and dried blood spot clinical samples to improve the efficiency and decrease the cost of subsequent WGS. This is a method that can be applied to clinical samples infected with other malaria species, such as *P. malariae*, *P. ovale curtisi*, and *P. ovale wallikeri*, where parasite densities are low, and where there is no routine *ex vivo* culture ([@B31]), though species-specific primer sets would likely be required. SWGA utilizes readily available reagents, does not require processing at the time of sample collection, and can be performed in a simple, overnight reaction. While several methods have been used successfully to enrich *P. vivax* gDNA for WGS from infected whole-blood samples, most are resource and labor intensive. Short-term *ex vivo* culture of *P. vivax* isolates or adaptation to growth in monkeys produces a large amount of *P. vivax* DNA, but these methods require significant resources. Single-cell sequencing allows for highly sensitive dissection of multiclonal samples; however, this approach requires cryopreserved samples and specialized laboratory equipment ([@B20]). While leukocyte filtration is cost-effective and efficient, it is not always possible to perform at field sites with limited infrastructure, because samples require refrigeration within 6 hours to minimize white blood cell lysis and reduce irreversible contamination from human DNA. Hybrid selection is less labor intensive, but the production of the RNA baits used for capture requires either large amounts of *P. vivax* Sal-1 DNA or costly commercially synthesized RNA bait.

Using SWGA, we achieved a higher-than-average callable *P. vivax* genome than was obtained for leukocyte-depleted clinical samples sequenced at a similar depth. SWGA generally yielded the highest genome coverage for clinical samples with the highest parasite densities, consistent with our experience with *P. falciparum* ([@B22]). For the 12 samples with parasite densities of \>5,000 parasites/µl (0.1% parasitemia), we were able to call, on average, 71.5% of the core genome, compared to 37% for the 6 samples with parasite densities of \<5,000 parasites/µl. Increased sequencing effort is needed to obtain maximal genome coverage for samples with lower parasite densities (see [Table S2](#tabS2){ref-type="supplementary-material"} and [Fig. S6](#figS6){ref-type="supplementary-material"} in the supplemental material). In these cases, the low genome coverage is likely the result of stochastic amplification of a small number of starting *P. vivax* genomes, which leads to very deep coverage of some genomic regions and little or no coverage of others ([@B22]). If maximal genome coverage is desired, sequential SWGA reactions with pvset1920 followed by pvset1 increase coverage slightly (3 to 5% 1× genome coverage) (see [Fig. S7](#figS7){ref-type="supplementary-material"}). Additionally, performing multiple independent SWGA reactions on a sample and combining the sequencing reads can improve genome coverage (4 to 12% 1× genome coverage) (see [Fig. S8](#figS8){ref-type="supplementary-material"}). Since multiple rounds of SWGA or pooling the products from multiple reactions increases the workload and expenses for a small improvement in genome coverage, we opted for a single amplification reaction with pvset1920 for our samples. However, these protocol modifications may be useful if high genome coverage is needed from samples with low parasitemia.
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Combinatorial testing of SWGA primer sets on three *P. vivax*-infected patient samples. Each panel represents the results obtained for one of the three individual patient samples (samples 6, 2, and 4) after one round of SWGA with primer set pvset1920 (red) or pvset1 (blue), after two rounds of SWGA with the same primer set (dark red for pvset1920 and dark blue for pvset1), or after two rounds of SWGA with different primer sets (yellow for pvset1920 followed by pvset1 and light blue for pvset1 followed by pvset1920). For all primer set combinations, the percentage of the *P. vivax* reference genome covered at ≥1× is shown relative to the total sequencing depth (in millions of base pairs sequenced) generated on a MiSeq (Illumina). Download FIG S6, TIF file, 31.4 MB.
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Impact of multiple independent SWGA reactions per sample on *P. vivax* genome coverage. Each panel represents the results obtained for a single patient sample (samples 16, 7, and 14). The percentage of the *P. vivax* reference genome covered at ≥1× is shown relative to the total sequencing depth generated on an Illumina MiSeq (in millions of base pairs sequenced) for each individual SWGA reaction (red) or pooled reads from the two independent SWGA reactions (black). Download FIG S7, TIF file, 31.4 MB.
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*P. vivax* genome coverage for samples with high, medium, and low parasite densities. The percentages of the *P. vivax* reference genome covered at ≥1× are shown relative to the total sequencing depth generated on an Illumina HiSeq (in millions of base pairs sequenced) for samples with high (red), medium (green), and low (blue) parasite densities. Download FIG S8, TIF file, 11.3 MB.

Copyright © 2017 Cowell et al.

2017

Cowell et al.

This content is distributed under the terms of the

Creative Commons Attribution 4.0 International license

.

10.1128/mBio.02257-16.10

Analysis of coverage relative to base pairs of sequencing effort for samples with high, medium, or low parasite densities. Download TABLE S2, DOCX file, 0.01 MB.
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One potential limitation of SWGA of *P. vivax* from clinical samples is the ability to amplify all clones in a multiclonal sample. One of our samples appeared to be multiclonal by microsatellite analysis of the unamplified gDNA, and yet, *F*~*ws*~ analysis of the post-SWGA sequence suggested that the sample was comprised of a single clone. It is possible that in this case, a majority clone was amplified preferentially over minority clones. Another possibility is that the microsatellite marker assessment may overestimate clonality. Analyses of additional multiclonal samples will be necessary to address this question. Another important limitation of SWGA is that copy number variant (CNV) detection is not possible on post-SWGA sequences. The uneven distribution of primer-targeted motifs in the target genome results in peaks and troughs in mean genome coverage that can confound CNV detection methods. Finally, SWGA requires long strands of gDNA for efficient amplification of the target genome and is unlikely to work well on degraded or ancient DNA samples.

Whole-genome analysis has the potential to reveal much about the biology and epidemiology of *P. vivax* infections. For example, comparison of recurrent infections using WGS can help distinguish relapse due to reactivation of hypnozoites from reinfection or drug resistance, an epidemiological distinction of public health importance. SWGA enables high-quality and cost-effective WGS of *P. vivax* from unprocessed blood samples that would otherwise be impossible or prohibitively expensive to sequence. Advanced technologies like SWGA will greatly facilitate future *P. vivax* whole-genome sequencing projects, thereby improving our ability to understand and combat the most widespread form of malaria.

MATERIALS AND METHODS {#s3}
=====================

Patient sample collection and preparation. {#s3.1}
------------------------------------------

The *P. vivax*-infected DNA sample used for initial testing of selective amplification primer sets (MRL2) was provided by the Malaria Reference Laboratory of the London School of Hygiene and Tropical Medicine, London, United Kingdom. The six dried blood spot samples used in this study were collected from patients with symptomatic *P. vivax* infection in Peru. Parasitemia was quantified with real-time PCR, and gDNA was extracted using a QIAamp DNA blood minikit (Qiagen).

Eighteen whole-blood samples used for additional testing and further sequencing analysis were derived from whole-blood samples collected from patients with symptomatic *P. vivax* infections from two sites around Iquitos, Peru, during a study conducted by U.S. Naval Medical Research Unit No. 6 ([@B32]). Thick blood smears were examined to identify the parasite species and to determine the level of parasitemia. Parasite density was calculated by counting the number of asexual parasites per 200 white blood cells in the thick smear (Assuming an average of 6,000 white blood cells per µl). Each blood smear was examined by two microscopists independently and by a third microscopist in the event of a discrepancy. The final parasite density was calculated as the average of the density readings from the two concordant microscopists. Whole-blood samples were collected in the field using EDTA-containing Vacutainer tubes. Samples were frozen and transported to the central laboratory until further processing. DNA was isolated from thawed whole blood using a QIAamp DNA blood minikit (Qiagen) following the manufacturer's recommendations and as described elsewhere ([@B33]). Samples were subsequently resuspended in Tris-EDTA (TE) buffer, and gDNA was quantified using a Qubit 2.0 fluorometer.

Primer design. {#s3.2}
--------------

The initial set of pvset1 primers was designed as described previously ([@B22]). Primer set pvset1920 was designed using the *swga* program, which scores primer sets based on their selectivity and evenness of binding (measured using the Gini index) and, thus, automates and improves primer selection. The source code of *swga*, along with download links and documentation, are available at <https://www.github.com/eclarke/swga>. pvset1920 was designed to specifically amplify longer regions (\>195,000 bp) of the *P. vivax* reference genome (Sal-1) that were GC rich (48.5 to 50.6%) and yielded low genome coverage following SWGA with pvset1. A total of 1,939 primer sets were identified that exhibited a minimum background binding distance of 25,000 bp and a maximum foreground binding distance of 37,000 bp. These were scored using *swga*'s composite primer scoring algorithm (Gini score × foreground mean/background mean), and the set with the lowest score (pvset1920) was chosen for testing.

pvset1 consists of the following 10 primers, with asterisks indicating phosphorothioate bonds that are necessary to prevent degradation by phi29: 5′-CGTTG\*C\*G-3′, 5′-TTTTTTC\*G\*C-3′, 5′-TCGTG\*C\*G-3′, 5′-CGTTTTTT\*T\*T-3′, 5′-TTTTTTTC\*G\*T-3′, 5′-CCGTT\*C\*G-3′, 5′-CGTTTC\*G\*T-3′, 5′-CGTTTC\*G\*C-3′, 5′-CGTTTT\*C\*G-3′, and 5′-TCGTTC\*G\*T-3′. pvset1920 consists of the following 12 primers: 5′-AACGAAGC\*G\*A-3′, 5′-ACGAAGCG\*A\*A-3′, 5′-ACGACGA\*A\*G-3′, 5′-ACGCGCA\*A\*C-3′, 5′-CAACGCG\*G\*T-3′, 5′-GACGAAA\*C\*G-3′, 5′-GCGAAAAA\*G\*G-3′, 5′-GCGAAGC\*G\*A-3′, 5′-GCGGAAC\*G\*A-3′, 5′-GCGTCGA\*A\*G-3′, 5′-GGTTAGCG\*G\*C-3′, and 5′-AACGAAT\*C\*G-3′.

Selective whole-genome amplification. {#s3.3}
-------------------------------------

Thirty to 70 ng of input DNA was added to a 50-µl reaction mixture containing 3.5 µM SWGA primers, 30 U phi29 DNA polymerase enzyme (New England Biolabs), 1× phi29 buffer (New England Biolabs), 4 mM dNTPs (Roche), 1% bovine serum albumin, and water. The reaction was carried out on a thermocycler with cycling conditions consisting of a ramp down from 35°C to 30°C (10 min per degree), 16 h at 30°C, 10 min at 65°C, and hold at 4°C. The samples were diluted 1:1 with DNase-free, RNase-free water and purified with AMPure XP beads (Beckman-Coulter) at a 1:1 ratio according to the manufacturer's protocol. When a second round of selective amplification was performed, the reaction mixture contained 100 to 200 ng of the AMPure XP-purified product from the first reaction.

Methylation digest. {#s3.4}
-------------------

One hundred twenty-five to 500 ng of gDNA extracted from *P. vivax*-infected whole-blood samples was digested with 5 units of FspEI (New England Biolabs) and 5 units of MspJI (New England Biolabs) enzymes in a 30-µl reaction mixture. A mock digest with an identical amount of gDNA and no enzymes was run in parallel. Samples were digested for 2 h at 37°C and then heat inactivated at 80°C for 15 min. For coverage analysis, rarefaction analysis was performed on Illumina MiSeq sequencing reads derived from samples digested with MspJI or FspEI (digest and SWGA) or mock digested with no enzyme prior to SWGA with primer set pvset1920. The coverage obtained by mapping 200,000 MiSeq sequencing reads (\~25 million bp of sequencing depth) was compared between digested and mock-digested samples. *P* values were obtained using the two-tailed *t* test.

Whole-genome sequencing. {#s3.5}
------------------------

The SWGA products and unamplified DNA used for primer set testing were sequenced on an Illumina MiSeq using a modified Nextera library preparation method. For HiSeq runs, next-generation-sequencing libraries of SWGA products were prepared using the Nextera XT DNA preparation kit (Illumina) according to the manufacturer's protocol. These samples were pooled and clustered on a HiSeq 2500 (Illumina) in Rapid Run mode with 100-bp paired-end reads. For the coverage analysis of leukocyte-filtered samples, fastq files from a prior study of *P. vivax* field samples ([@B10]) were used.

Raw fastq files were aligned to the Sal-1 reference genome (PlasmoDB version 13, <http://plasmodb.org/common/downloads/release-13.0/PvivaxSal1/fasta/data/>) using the Burroughs-Wheeler Aligner (version 0.7.8) ([@B34]) and SAMtools (version 0.1.19) ([@B35], [@B36]) in the Platypus pipeline, as previously described ([@B37]). Picard (version 2.0.1) was used to remove unmapped reads, and the Genome Analysis Toolkit (GATK) ([@B38]) was used to realign the sequences around the indels. Picard's CollectGcBiasMetrics tool was used to generate the GC bias plots. GATK's DepthOfCoverage tool was used to determine the percentages of the total and core genomes covered by ≥5 reads, mean coverage, and coverage over the core genome. The coordinates of the *P. vivax* core genome, which excludes subtelomeric and hypervariable regions with significantly higher read mapping errors, was obtained from a recent analysis of hundreds of *P. vivax* sequences from clinical isolates ([@B15]).

For rarefaction analyses, sequences were aligned with smalt (Wellcome Trust Sanger Institute) and mapped with custom scripts in R (<https://www.r-project.org>/). To visualize base composition across chromosomes, plots were created in Geneious (version 9.1) ([@B39]) using the Sal-1 *P. vivax* reference sequences and 25-bp windows. Plots of chromosome coverage were created with IGVTools (version 2.3.40) ([@B40], [@B41]).

Variant calling and analysis. {#s3.6}
-----------------------------

We followed the GATK's best practices to call variants ([@B42], [@B43]). The aligned sequences were run through GATK's HaplotypeCaller in "reference confidence" mode to create genomic variant call format (GVCF) files for each sample. This reference confidence model highlights areas of the genome that are likely to have variation and produces a comprehensive record of genotype likelihoods and annotations for each site. The samples were joint genotyped using the GenotypeGVCFs tool.

Variants were further filtered based on quality scores and sequencing bias statistics based on default parameters from GATK. SNPs were filtered out if they met any of the following criteria: quality depth (QD) of \<2.0, mapping quality (MQ) of \<50.0, Phred-scaled *P* value using Fisher's exact test to detect strand bias (FS) of \>60.0, symmetric odds ratio (SOR) of \>4.0, *Z* score from Wilcoxon rank-sum test of alternative versus reference read-mapping qualities (MQRankSum) of \<−12.5, and ReadPosRankSum (RPRS) of \<−8.0. Variants were annotated using snpeff (version 4.2) ([@B44]).

*F*~*ws*~ of samples with the highest genome coverage was estimated using *moimix* (<https://doi.org/10.5281/zenodo.58257>), a package available through R. The package calculates the *F*~*ws*~ statistic using the equation *F*~*ws*~ = 1 − (*H~w~/H~s~*), where *H*~*w*~ is the within-host heterozygosity and *H*~*s*~ is the population-level heterozygosity ([@B5], [@B30]). The core *P. vivax* genome, as defined by Pearson et al. ([@B15]), was used for core-genome analysis. For microsatellite genotyping, five neutral microsatellite loci of significant variability in the Peruvian Amazon were typed in a previous study ([@B32]). If there was more than one marker at any given locus, the sample was considered multiclonal, per prior genotyping studies ([@B45][@B46][@B47]).

A neighbor-joining tree was constructed using SNPs from the core *P. vivax* genome from sequences obtained in this study, along with sequences from previously published studies that are available in the NCBI Short Read Archive. The Mdio samples were from a previous study conducted by our laboratory in Peru ([@B10]), and the rest of the sequences were obtained from two recent large-scale *P. vivax* sequencing studies ([@B15], [@B17]). In order to assess the phylogenetic relationships of sequenced isolates, we constructed a multiple sequence alignment from filtered SNPs called in GATK using an in-house Perl script. This alignment was used as the input for maximum-likelihood phylogenetic analysis in the randomized accelerated maximum-likelihood program (RAxML) ([@B48]) with 500 pseudoreplicates using the generalized time-reversible model, and the resulting tree was visualized in Dendroscope ([@B49]).

Ethics approval and consent to participate. {#s3.7}
-------------------------------------------

The sample from Malaria Research Laboratories (MRL) was an anonymized DNA sample previously collected by the MRL and provided under the MRL's remit to undertake epidemiological surveillance relevant to imported malaria in the United Kingdom. The protocol for the collection of field samples was approved by the Institutional Review Board of the U.S. Naval Medical Research Center (Protocol NMRCD.2005.0005) and the National Institutes of Health of Peru (protocol 009-2004) in compliance with all applicable federal regulations governing the protection of human subjects. All adult subjects provided written informed consent, and all children 8 to 17 years old provided verbal assent to participate in the study.

Accession number(s). {#s3.8}
--------------------

The *P. vivax* genome Illumina sequencing reads of the 22 samples used for variant analysis in this study are available in the National Center for Biotechnology Information's Sequence Read Archive with the study accession number [SRP095853](https://www.ncbi.nlm.nih.gov/sra/?term=SRP095853).
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